Stage IV superficial spreading melanoma represents the most advanced phase of this common skin cancer, where the disease has traveled beyond its original location to distant parts of the body. While this diagnosis presents serious challenges, evolving treatment approaches are offering patients new hope, with strategies designed to control cancer growth, manage symptoms, and in some cases, extend survival significantly.

Understanding Treatment Goals in Advanced Melanoma

When superficial spreading melanoma reaches stage IV, the cancer has moved from the skin to other organs or distant areas of the body. At this advanced stage, the primary focus of treatment shifts from cure alone to controlling the disease and maintaining quality of life. The cancer may have spread to places such as the lungs, liver, bones, brain, lymph nodes far from the original tumor, or even to soft tissues including muscles, nerves, and blood vessels throughout the body.^[1]

Treatment decisions for stage IV superficial spreading melanoma depend on several important factors. Your doctor will consider where exactly the cancer has spread, how many areas are affected, your overall health and fitness level, and how well your body might tolerate different therapies. Unlike earlier stages where removing the cancer completely is often possible, stage IV treatment aims to shrink tumors, slow disease progression, relieve uncomfortable symptoms, and help patients live longer with a better quality of life.^[1]

Medical professionals now have more tools than ever before to manage advanced melanoma. The treatment landscape has changed dramatically over the past decade, with new therapies that work differently from traditional approaches. Some treatments help the immune system recognize and attack cancer cells, while others target specific genetic changes within melanoma cells. This variety means doctors can often customize treatment plans based on the unique characteristics of each patient’s cancer.^[4]

It’s important to understand that stage IV melanoma is considered advanced cancer, and treatment is typically ongoing rather than a short course of therapy. Patients often work closely with a team of specialists including dermatologists, oncologists, surgeons, and other healthcare professionals who coordinate care. Regular monitoring through scans and blood tests helps the team understand whether treatments are working and when adjustments might be needed.^[1]

Standard Treatment Approaches

Surgery remains an important option for stage IV melanoma when the cancer has spread to only a few specific locations that can be safely removed. If metastases—areas where cancer has spread—are limited and accessible, surgical removal can help control the disease and reduce symptoms. However, surgery alone is rarely sufficient at this stage, and doctors typically combine it with other treatments to address cancer cells that might remain in the body.^[1]

Immunotherapy has become a cornerstone of standard treatment for advanced melanoma. These medications work by unleashing the body’s own immune system to recognize and destroy melanoma cells. The immune system normally has built-in checkpoints that prevent it from attacking the body’s own tissues, but cancer cells can exploit these checkpoints to hide from immune surveillance. Checkpoint inhibitors are drugs that block these protective mechanisms, allowing immune cells to identify and eliminate cancer.^[1]

Common checkpoint inhibitors used for melanoma include medications that target proteins called PD-1, PD-L1, and CTLA-4. These drugs are given through intravenous infusion, typically every few weeks. The treatment duration varies depending on how well the cancer responds and how the patient tolerates the medication. Some patients continue immunotherapy for months or even years, while others may stop earlier if they experience complete tumor shrinkage or problematic side effects.^[1]

Targeted therapy represents another major treatment category for stage IV melanoma. These medications work differently from immunotherapy—instead of stimulating the immune system, they attack specific genetic mutations found in melanoma cells. Many superficial spreading melanomas contain a mutation in a gene called BRAF, which makes cells grow uncontrollably. Targeted drugs called BRAF inhibitors can block this faulty protein, while companion drugs called MEK inhibitors block related proteins in the same growth pathway. These targeted therapies are usually taken as pills twice daily and are often used in combination for better effectiveness.^[1]

Radiation therapy plays an important supportive role in stage IV melanoma treatment, particularly when cancer has spread to the brain or bones. Radiation uses high-energy beams to kill cancer cells in specific locations. For brain metastases, specialized techniques like stereotactic radiosurgery can deliver precise radiation doses to tumors while minimizing damage to surrounding healthy brain tissue. Radiation to bones can reduce pain and prevent fractures in areas weakened by cancer.^[1]

A unique treatment option called talimogene laherparepvec, often abbreviated as T-VEC, involves injecting a modified herpes virus directly into melanoma tumors. This intralesional therapy causes cancer cells to burst open and die while also stimulating an immune response against the cancer. T-VEC is typically used when melanoma has spread to skin, lymph nodes, or other areas that can be accessed with a needle. Injections are given in a doctor’s office according to a specific schedule over several months.^[1]

For melanomas that have spread extensively within an arm or leg, doctors sometimes use specialized chemotherapy techniques called isolated limb perfusion or isolated limb infusion. These procedures deliver high doses of chemotherapy drugs directly to the affected limb while temporarily blocking blood flow to prevent the drugs from circulating throughout the body. This approach allows much higher drug concentrations in the treatment area while minimizing whole-body side effects.^[1]

Electrochemotherapy combines chemotherapy with brief electrical pulses delivered through electrodes placed on the skin. The electrical pulses create temporary openings in cancer cell membranes, allowing chemotherapy drugs to enter cells more effectively. This technique is used for melanoma tumors on or just under the skin surface and can be particularly helpful for treating painful or bleeding lesions.^[1]

Traditional intravenous chemotherapy is less commonly used for melanoma today compared to immunotherapy and targeted therapy, which generally work better. However, chemotherapy through the bloodstream remains an option for patients who cannot receive or have not responded to other treatments. Chemotherapy drugs work by interfering with cancer cell division and growth, but they also affect normal rapidly dividing cells, which explains many of their side effects.^[1]

Side effects vary considerably depending on which treatments are used. Immunotherapy can cause immune-related side effects because activating the immune system sometimes leads to inflammation in healthy organs. Patients may experience fatigue, skin rashes, diarrhea, or inflammation of organs like the thyroid, liver, or lungs. Most immune-related side effects can be managed with steroid medications or other immunosuppressive drugs if caught early. Targeted therapies often cause different side effects including skin problems, fever, fatigue, joint pain, and changes in heart function. Radiation therapy typically causes localized effects in the treatment area such as skin irritation, fatigue, and specific symptoms depending on what part of the body receives radiation.^[1]

Innovative Treatments in Clinical Trials

Clinical trials are research studies that test new treatments before they become widely available. For stage IV melanoma, clinical trials offer access to cutting-edge therapies that might provide benefits beyond what current standard treatments can achieve. Given how rapidly melanoma treatment is advancing, doctors strongly encourage patients with advanced disease to consider participating in clinical trials, both for initial treatment and if the cancer progresses despite standard therapies.^[4]

One area of active investigation involves combination immunotherapy approaches. Researchers are testing whether combining different checkpoint inhibitors or pairing immunotherapy with other treatment types can improve outcomes. Some trials combine immunotherapy with targeted therapy, radiation, or experimental medications that work through entirely new mechanisms. The goal is to attack melanoma from multiple angles simultaneously, potentially achieving better tumor control than single treatments alone.^[4]

New immunotherapy agents are being developed that target different immune system checkpoints beyond those currently in standard use. These experimental checkpoint inhibitors aim to activate immune responses through alternative pathways, offering hope for patients whose melanoma doesn’t respond to existing immunotherapies. Phase I trials typically test these new agents for safety, Phase II trials assess whether they effectively shrink tumors, and Phase III trials compare them directly against standard treatments to determine if they offer superior outcomes.^[4]

TIL therapy, which stands for tumor-infiltrating lymphocyte therapy, represents an innovative form of cellular immunotherapy. This approach involves removing a piece of the patient’s tumor and isolating immune cells that have naturally migrated into the cancer. These immune cells are then grown in large numbers in a laboratory over several weeks and infused back into the patient after the patient receives chemotherapy to make room for them. TIL therapy harnesses immune cells that have already shown the ability to recognize the patient’s specific melanoma, potentially creating a powerful personalized treatment.^[4]

Cancer vaccines for melanoma are being explored in clinical trials. Unlike preventive vaccines that stop infections, therapeutic cancer vaccines aim to train the immune system to recognize and attack cancer cells. Some vaccines use pieces of melanoma proteins, while others use modified viruses or the patient’s own tumor cells to stimulate immunity. These vaccines are often combined with other immunotherapies to enhance their effectiveness.^[4]

Researchers are investigating new targeted therapies that block different molecular pathways involved in melanoma growth. Beyond BRAF and MEK inhibitors, scientists are developing drugs that target other genetic mutations found in smaller subsets of melanoma patients. These include inhibitors of proteins called KIT, NRAS, and others. By expanding the range of targetable mutations, researchers hope to provide effective treatment options for more patients.^[4]

Oncolytic virus therapy uses viruses that have been modified to infect and kill cancer cells while sparing normal cells. T-VEC, mentioned earlier, is one example that has already received regulatory approval. Newer oncolytic viruses are being tested that may work even better or can be delivered differently, such as through intravenous infusion rather than direct injection into tumors. These viruses not only destroy cancer cells directly but also release tumor proteins that help the immune system recognize and attack remaining cancer cells.^[1]

Some clinical trials focus on understanding why certain melanomas become resistant to treatment. Researchers are testing agents that might overcome or prevent resistance to immunotherapy or targeted therapy. These include drugs that modify the tumor environment, block new blood vessel formation that feeds tumors, or interfere with the ways cancer cells protect themselves from treatment.^[4]

Preliminary results from various trials have shown encouraging signs. Some combination immunotherapy approaches have demonstrated higher response rates—meaning more patients experience tumor shrinkage—compared to single-agent treatments. Certain trials have reported improved progression-free survival, which measures how long patients go without their cancer worsening. Safety profiles for many experimental treatments appear manageable, with side effects similar to or only moderately worse than existing therapies. However, it’s crucial to understand that clinical trial results are preliminary until studies are completed and findings are confirmed in large patient populations.^[4]

Patients interested in clinical trials can search databases that list ongoing studies, talk with their oncologists about potentially suitable options, or seek second opinions at major cancer centers that conduct extensive melanoma research. Participation in trials is voluntary, and patients can withdraw at any time. Trials typically provide experimental treatments at no cost, though patients may still have expenses for standard care aspects like hospital stays and routine tests.^[4]

Most common treatment methods

• Surgery
  • Removal of metastases when cancer has spread to only a few accessible locations
  • Often combined with other therapies rather than used alone at stage IV
  • Can help control disease and reduce symptoms in selected patients
• Immunotherapy
  • Checkpoint inhibitors that target PD-1, PD-L1, or CTLA-4 proteins
  • Works by enabling the immune system to recognize and attack melanoma cells
  • Given through intravenous infusion on a regular schedule
  • May cause immune-related side effects affecting various organs
  • Treatment duration varies based on response and tolerability
• Targeted therapy
  • BRAF inhibitors and MEK inhibitors for melanomas with BRAF mutations
  • Blocks specific faulty proteins that drive cancer cell growth
  • Usually taken as oral medications twice daily
  • Requires genetic testing of tumor tissue to determine eligibility
  • Common side effects include skin problems, fever, fatigue, and joint pain
• Radiation therapy
  • Used particularly for brain metastases and bone metastases
  • Stereotactic radiosurgery delivers precise radiation to brain tumors
  • Can reduce pain and prevent fractures in bone metastases
  • Causes localized side effects in the treatment area
• Intralesional therapy
  • Talimogene laherparepvec (T-VEC) injected directly into accessible tumors
  • Uses modified herpes virus to destroy cancer cells and stimulate immunity
  • Given in a doctor’s office according to a specific schedule
• Regional chemotherapy
  • Isolated limb perfusion or infusion for melanomas extensively spread within an arm or leg
  • Delivers high-dose chemotherapy to the limb while protecting the rest of the body
  • Electrochemotherapy combines chemotherapy with electrical pulses for skin lesions
• Systemic chemotherapy
  • Traditional intravenous chemotherapy less commonly used today
  • Reserved for patients who cannot receive or haven’t responded to other treatments
  • Works by interfering with cancer cell division and growth